Department of Psychiatry
The Yale Department of Psychiatry is a world leader in patient care, research, and education. Our department prides itself on its diverse and talented faculty, including a cadre of compassionate clinicians, inter-disciplinary teams of talented investigators, and numerous committed and dedicated teachers, as well as a network of able alumni that remain vital to our missions.
As a department, we not only provide the highest quality of patient care, but also lead the nation in discoveries that are transforming our understanding and treatment of mental illness and addiction.
The department’s Psychology Section, with more than 200 full-time and voluntary faculty, is one of the largest and most accomplished groups of psychologists in an academic medical center.
Latest News
- June 08, 2023
Pearlson Speaks on Cannabis, Psychosis at 19th Annual Flor-Henry Lectures
- June 08, 2023
Cooper Awarded Lifetime Achievement Award From Academy of Eating Disorders
- June 07, 2023Source: Prevention TTASC
Connecticut Prevention Professional Spotlight: Melvin Wells III
- June 07, 2023
Harvanek Receives Yale Physician Scientist Development Award
- June 07, 2023Source: The Wall Street Journal
The Science Behind Sound Therapy
- June 06, 2023
Childs, Cortes-Briones Awarded Grants at Yale Innovation Summit
- June 05, 2023
Sinha Elected Vice President; Mason on Board of Research Society on Alcohol
- June 05, 2023Source: Newsweek
Student Loan Forgiveness Is a Racial Justice Issue. The Senate Is Wrong to Overturn Biden's Plan
Pioneering Interventional Psychiatric Services: Yale School of Medicine and Yale New Haven Health
00:02:46
Ketamine Clinical Trial
Parkinson disease not only affects a person's mobility, but also many other symptoms in a person with Parkinson disease life. Depression is a very common symptom caused by Parkinson disease, and adequate treatment is imperative for patients to feel their best. Through collaborations between Drs. Sophie E. Holmes and Gerard Sanacora of Psychiatry and the Movement Disorders group, researchers are conducting the first clinical trial of ketamine as an antidepressant in PD. Due to how it works in the brain – its ability to help form new synapses – they have strong reason to believe it will effectively treat depression, and possibly other symptoms, in PD. Using brain imaging before and after treatment will help to determine how it works in the brains of people with Parkinson’s for the first time. The trial is taking place at the Yale New Haven Psychiatric Hospital. In this video, hear more about the trial from Drs. Holmes and Sanacora and from Brenda, who talks about her experience participating in this groundbreaking research.
Department of Psychiatry Upcoming Events
Everyone 2:00 PM3:00 PMRobert Kerns, PhD
Everyone 10:15 AM11:30 AMJohn Krystal, MD
School Only 12:00 PM1:00 PMTomasz Nowakowski, PhD
Department of Psychiatry Diversity, Equity and Inclusion Upcoming Events
Everyone 2:00 PM3:00 PMRobert Kerns, PhD
Everyone 10:15 AM11:30 AMJohn Krystal, MD
School Only 12:00 PM1:00 PMTomasz Nowakowski, PhD